Loading...
Concentra Group Holdings Q1 2025 Earnings Report
Concentra Group Holdings reported its first quarter 2025 earnings, cash dividend, and revised FY 2025 guidance.
Key Takeaways
Concentra reported a solid start to 2025 with strong revenue and Adjusted EBITDA growth in the first quarter, driven by organic and inorganic growth, including the acquisition of Nova Medical Centers and the launch of new de novo centers.
Revenue increased by 7.1% to $500.8 million in Q1 2025.
Net income was $40.6 million, with earnings per common share of $0.30.
Adjusted EBITDA grew by 6.8% to $102.7 million.
The company completed the acquisition of Nova Medical Centers and launched three de novo centers, expanding its occupational health footprint.
Revenue by Segment
Forward Guidance
Concentra raised its financial guidance for 2025 based on strong Q1 results and additional development activity.
Positive Outlook
- Revenue expected in the range of $2.1 billion to $2.15 billion.
- Adjusted EBITDA expected in the range of $415 million to $430 million.
- Net leverage ratio expected to be approximately 3.5x.
- Continued focus on key drivers of growth and delivering comparative market advantage.
- Effective and efficient integration of acquired centers and businesses.
Challenges Ahead
- The frequency of work-related injuries and illnesses could impact results.
- Adverse changes to relationships with employer customers or payors could affect performance.
- Changes to regulations or new interpretations of existing regulations may pose challenges.
- Labor shortages, increased employee turnover, or costs could significantly increase operating costs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...